Skip to main content
OLIPASS CORPORATION logo

OLIPASS CORPORATION — Investor Relations & Filings

Ticker · 244460 ISIN · KR7244460002 KO Professional, scientific and technical activities
Open in API
Filings indexed 505 across all filing types
Latest filing 2025-02-14 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 244460

About OLIPASS CORPORATION

https://www.olipass.com/front/eng/index…

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed by Olipass Co., Ltd. It details the issuance of new shares, the purpose of the funds (operating and acquisition), the third-party allocation details, and the impact on the company's largest shareholder. This is a formal regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-02-14 Korean
[기재정정]채무인수결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Debt Assumption Decision' (채무인수결정). It details changes to the debt assumption date and provides context on the financial transaction. Since this is a specific regulatory disclosure regarding corporate financing and debt obligations that does not fit into categories like M&A, dividends, or earnings, it is classified as a general Regulatory Filing (RNS).
2025-01-31 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고) regarding a previous 'Major Matter Report' (주요사항보고서) concerning the acquisition of tangible assets (유형자산 양수 결정). It details changes to the acquisition date and payment schedule. In the context of Korean regulatory filings (DART), this is a standard corporate disclosure regarding material business transactions. Since it does not fit into specific categories like M&A (which usually refers to corporate mergers/takeovers) or capital changes, it falls under the general regulatory filing category.
2025-01-31 Korean
자산재평가결과(자율공시)
Regulatory Filings Classification · 100% confidence The document is a formal disclosure regarding the results of an asset revaluation (자산재평가결과) for the company Olipass. It details the revaluation of land and buildings, the financial impact on assets and equity, and the accounting treatment. Since this is a specific regulatory disclosure regarding corporate assets and financial position that does not fit into the other specialized categories like 10-K, IR, or CAP, it is classified as a general Regulatory Filing (RNS).
2025-01-24 Korean
투자판단관련주요경영사항 (무형자산(봉합사 기술 특허 4건) 기술가치평가 결과에 관한 건)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Olipass) titled 'Investment Judgment Related Major Management Matters'. It details the valuation results of four specific intangible assets (patents) conducted by an external evaluation agency. This type of disclosure, which reports on material corporate events or asset valuations that do not fit into specific categories like dividends or share issues, is classified as a general regulatory filing.
2025-01-23 Korean
내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Delisting Announcement Classification · 100% confidence The document is a regulatory filing from a Korean company (Olipass) regarding 'Internal Closing Financial Results' and the occurrence of grounds for administrative designation, delisting, and eligibility review. It provides financial data (revenue, profit/loss, capital status) based on internal closing before the final audit. This type of disclosure is a standard regulatory announcement in the Korean market (DART system) regarding financial status and potential listing risks, which falls under the 'Regulatory Filings' category as it is a mandatory disclosure of material corporate events.
2025-01-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.